Abstract 278P
Background
The advent of trastuzumab deruxtecan has led to the creation of a new treatment criterion for low HER2 expression (HER2-low : HER2 IHC score of 1+ or 2+/ISH not amplified). Utilizing 40 years of detailed clinical data from our hospital, the study aimed to investigate clinicopathological factors and long-term prognosis in HER2-low and HER2-zero breast cancer.
Methods
A total of 4,810 early-stage breast cancer cases were operated on and followed up from 1981 to 2022 at our hospital. We analyzed HER2 expression status in tumor tissues, clinicopathological factors, and prognosis in 3,788 cases excluding stage 0 cases.
Results
HER2-low cases accounted for 48% (1,819/3,788) of all cases analyzed, while HER2-zero cases comprised 34% (1,280/3,788). Among HER2-low cases, 89% were hormone receptor (HR) positive, with 11% classified as triple-negative (TN) breast cancer. In contrast, 83% of HER2-zero cases were HR positive, while 17% exhibited TN. Notably, HER2-zero cases showed a higher proportion of TN compared to HER2-low cases.
Prognostic analysis showed that the HER2-low group exhibited significantly superior outcomes in both disease-free survival (DFS) and overall survival (OS) compared to the HER2-zero group (p=0.005, p
Conclusions
In early-stage breast cancer, HER2-low patients had a better prognosis than HER2-zero patients, suggesting that HER2 expression status may result in different outcomes due to different hormone receptor expression rates and sensitivity to drug therapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Toyama: Non-Financial Interests, Personal and Institutional, Invited Speaker: Eli Lilly, Pfizer, Daiichi Sankyo, Chugai, Kyowa Kirin, Eisai; Non-Financial Interests, Personal, Invited Speaker: Taiho, AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
364P - Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase Ib/II study
Presenter: Eva Ciruelos
Session: Poster session 14
365P - Interim analysis (IA) of the giredestrant (G) + samuraciclib (SAMURA) arm in MORPHEUS breast cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)
Presenter: Mafalda Oliveira
Session: Poster session 14
366P - Exploring the benefit of combining paclitaxel with capivasertib treatment in PI3K/AKT/PTEN-altered and non-altered TNBC preclinical models
Presenter: Cath Eberlein
Session: Poster session 14
367P - Phase I/II dose escalation study evaluating first-in-class eIF4A inhibitor zotatifin in ER+ metastatic breast cancer
Presenter: Ezra Rosen
Session: Poster session 14
368P - Tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR+/HER2- advanced breast cancer after CDK4/6 inhibitors: Preliminary findings of a multi-center, phase II study
Presenter: Qiufan Zheng
Session: Poster session 14
370P - A phase Ib study to evaluate the efficacy and safety of afuresertib plus fulvestrant in subjects with locally advanced or metastatic HR+/HER2- breast cancer who failed standard of care therapies: A subgroup analysis of efficacy in PIK3CA/AKT1/PTEN-altered subjects
Presenter: Pin Zhang
Session: Poster session 14
371P - Efficacy of metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: The phase III MECCA trial
Presenter: Shusen Wang
Session: Poster session 14